Table of Content

1 Study Coverage
1.1 Opioid-Induced Constipation Product Introduction
1.2 Market by Type
1.2.1 Global Opioid-Induced Constipation Market Size Growth Rate by Type
1.4.2 Methylnaltrexone Bromide
1.4.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
1.3 Market by Application
1.3.1 Global Opioid-Induced Constipation Market Size Growth Rate by Application
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Opioid-Induced Constipation Sales Estimates and Forecasts 2016-2027
2.2 Global Opioid-Induced Constipation Revenue Estimates and Forecasts 2016-2027
2.3 Global Opioid-Induced Constipation Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top Opioid-Induced Constipation Regions by Sales
2.4.1 Global Top Opioid-Induced Constipation Regions by Sales (2016-2021)
2.4.2 Global Top Opioid-Induced Constipation Regions by Sales (2022-2027)
2.5 Global Top Opioid-Induced Constipation Regions by Revenue
2.5.1 Global Top Opioid-Induced Constipation Regions by Revenue (2016-2021)
2.5.2 Global Top Opioid-Induced Constipation Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Opioid-Induced Constipation Sales by Manufacturers
3.1.1 Global Top Opioid-Induced Constipation Manufacturers by Sales (2016-2021)
3.1.2 Global Top Opioid-Induced Constipation Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by Opioid-Induced Constipation Sales in 2020
3.2 Global Opioid-Induced Constipation Revenue by Manufacturers
3.2.1 Global Top Opioid-Induced Constipation Manufacturers by Revenue (2016-2021)
3.2.2 Global Top Opioid-Induced Constipation Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by Opioid-Induced Constipation Revenue in 2020
3.3 Global Opioid-Induced Constipation Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Opioid-Induced Constipation Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Opioid-Induced Constipation Sales by Type
4.1.1 Global Opioid-Induced Constipation Historical Sales by Type (2016-2021)
4.1.2 Global Opioid-Induced Constipation Forecasted Sales by Type (2022-2027)
4.1.3 Global Opioid-Induced Constipation Sales Market Share by Type (2016-2027)
4.2 Global Opioid-Induced Constipation Revenue by Type
4.2.1 Global Opioid-Induced Constipation Historical Revenue by Type (2016-2021)
4.2.2 Global Opioid-Induced Constipation Forecasted Revenue by Type (2022-2027)
4.2.3 Global Opioid-Induced Constipation Revenue Market Share by Type (2016-2027)
4.3 Global Opioid-Induced Constipation Price by Type
4.3.1 Global Opioid-Induced Constipation Price by Type (2016-2021)
4.3.2 Global Opioid-Induced Constipation Price Forecast by Type (2022-2027)
5 Market Size by Application
5.1 Global Opioid-Induced Constipation Sales by Application
5.1.1 Global Opioid-Induced Constipation Historical Sales by Application (2016-2021)
5.1.2 Global Opioid-Induced Constipation Forecasted Sales by Application (2022-2027)
5.1.3 Global Opioid-Induced Constipation Sales Market Share by Application (2016-2027)
5.2 Global Opioid-Induced Constipation Revenue by Application
5.2.1 Global Opioid-Induced Constipation Historical Revenue by Application (2016-2021)
5.2.2 Global Opioid-Induced Constipation Forecasted Revenue by Application (2022-2027)
5.2.3 Global Opioid-Induced Constipation Revenue Market Share by Application (2016-2027)
5.3 Global Opioid-Induced Constipation Price by Application
5.3.1 Global Opioid-Induced Constipation Price by Application (2016-2021)
5.3.2 Global Opioid-Induced Constipation Price Forecast by Application (2022-2027)

6 North America
6.1 North America Opioid-Induced Constipation Market Size by Type
6.1.1 North America Opioid-Induced Constipation Sales by Type (2016-2027)
6.1.2 North America Opioid-Induced Constipation Revenue by Type (2016-2027)
6.2 North America Opioid-Induced Constipation Market Size by Application
6.2.1 North America Opioid-Induced Constipation Sales by Application (2016-2027)
6.2.2 North America Opioid-Induced Constipation Revenue by Application (2016-2027)
6.3 North America Opioid-Induced Constipation Market Size by Country
6.3.1 North America Opioid-Induced Constipation Sales by Country (2016-2027)
6.3.2 North America Opioid-Induced Constipation Revenue by Country (2016-2027)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Opioid-Induced Constipation Market Size by Type
7.1.1 Europe Opioid-Induced Constipation Sales by Type (2017-2027)
7.1.2 Europe Opioid-Induced Constipation Revenue by Type (2017-2027)
7.2 Europe Opioid-Induced Constipation Market Size by Application
7.2.1 Europe Opioid-Induced Constipation Sales by Application (2017-2027)
7.2.2 Europe Opioid-Induced Constipation Revenue by Application (2017-2027)
7.3 Europe Opioid-Induced Constipation Market Size by Country
7.3.1 Europe Opioid-Induced Constipation Sales by Country (2017-2027)
7.3.2 Europe Opioid-Induced Constipation Revenue by Country (2017-2027)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Opioid-Induced Constipation Market Size by Type
8.1.1 Asia Pacific Opioid-Induced Constipation Sales by Type (2018-2027)
8.1.2 Asia Pacific Opioid-Induced Constipation Revenue by Type (2018-2027)
8.2 Asia Pacific Opioid-Induced Constipation Market Size by Application
8.2.1 Asia Pacific Opioid-Induced Constipation Sales by Application (2018-2027)
8.2.2 Asia Pacific Opioid-Induced Constipation Revenue by Application (2018-2027)
8.3 Asia Pacific Opioid-Induced Constipation Market Size by Region
8.3.1 Asia Pacific Opioid-Induced Constipation Sales by Region (2018-2027)
8.3.2 Asia Pacific Opioid-Induced Constipation Revenue by Region (2018-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Opioid-Induced Constipation Market Size by Type
9.1.1 Latin America Opioid-Induced Constipation Sales by Type (2019-2027)
9.1.2 Latin America Opioid-Induced Constipation Revenue by Type (2019-2027)
9.2 Latin America Opioid-Induced Constipation Market Size by Application
9.2.1 Latin America Opioid-Induced Constipation Sales by Application (2019-2027)
9.2.2 Latin America Opioid-Induced Constipation Revenue by Application (2019-2027)
9.3 Latin America Opioid-Induced Constipation Market Size by Country
9.3.1 Latin America Opioid-Induced Constipation Sales by Country (2019-2027)
9.3.2 Latin America Opioid-Induced Constipation Revenue by Country (2019-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
6 Middle East and Africa
6.1 Middle East and Africa Opioid-Induced Constipation Market Size by Type
6.1.1 Middle East and Africa Opioid-Induced Constipation Sales by Type (2016-2027)
6.1.2 Middle East and Africa Opioid-Induced Constipation Revenue by Type (2016-2027)
6.2 Middle East and Africa Opioid-Induced Constipation Market Size by Application
6.2.1 Middle East and Africa Opioid-Induced Constipation Sales by Application (2016-2027)
6.2.2 Middle East and Africa Opioid-Induced Constipation Revenue by Application (2016-2027)
6.3 Middle East and Africa Opioid-Induced Constipation Market Size by Country
6.3.1 Middle East and Africa Opioid-Induced Constipation Sales by Country (2016-2027)
6.3.2 Middle East and Africa Opioid-Induced Constipation Revenue by Country (2016-2027)
6.3.3 Turkey
6.3.4 Saudi Arabia
6.3.5 U.A.E

11 Company Profiles
11.1 Takeda Pharmaceuticals
11.1.1 Takeda Pharmaceuticals Corporation Information
11.1.2 Takeda Pharmaceuticals Overview
11.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Description
11.1.5 Takeda Pharmaceuticals Related Developments
11.2 Bayer
11.2.1 Bayer Corporation Information
11.2.2 Bayer Overview
11.2.3 Bayer Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 Bayer Opioid-Induced Constipation Product Description
11.2.5 Bayer Related Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 Sanofi Opioid-Induced Constipation Product Description
11.3.5 Sanofi Related Developments
11.4 Mallinckrodt
11.4.1 Mallinckrodt Corporation Information
11.4.2 Mallinckrodt Overview
11.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.4.4 Mallinckrodt Opioid-Induced Constipation Product Description
11.4.5 Mallinckrodt Related Developments
11.5 Salix (Bausch Health)
11.5.1 Salix (Bausch Health) Corporation Information
11.5.2 Salix (Bausch Health) Overview
11.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Description
11.5.5 Salix (Bausch Health) Related Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Corporation Information
11.6.2 AstraZeneca Overview
11.6.3 AstraZeneca Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.6.4 AstraZeneca Opioid-Induced Constipation Product Description
11.6.5 AstraZeneca Related Developments
11.7 Progenics Pharmaceuticals
11.7.1 Progenics Pharmaceuticals Corporation Information
11.7.2 Progenics Pharmaceuticals Overview
11.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Description
11.7.5 Progenics Pharmaceuticals Related Developments
11.8 Purdue Pharm
11.8.1 Purdue Pharm Corporation Information
11.8.2 Purdue Pharm Overview
11.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.8.4 Purdue Pharm Opioid-Induced Constipation Product Description
11.8.5 Purdue Pharm Related Developments
11.9 Nektar Therapeutics
11.9.1 Nektar Therapeutics Corporation Information
11.9.2 Nektar Therapeutics Overview
11.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Description
11.9.5 Nektar Therapeutics Related Developments
11.10 Daiichi Sankyo
11.10.1 Daiichi Sankyo Corporation Information
11.10.2 Daiichi Sankyo Overview
11.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Description
11.10.5 Daiichi Sankyo Related Developments
11.1 Takeda Pharmaceuticals
11.1.1 Takeda Pharmaceuticals Corporation Information
11.1.2 Takeda Pharmaceuticals Overview
11.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Description
11.1.5 Takeda Pharmaceuticals Related Developments
11.12 GSK
11.12.1 GSK Corporation Information
11.12.2 GSK Overview
11.12.3 GSK Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.12.4 GSK Product Description
11.12.5 GSK Related Developments
11.13 Shionogi
11.13.1 Shionogi Corporation Information
11.13.2 Shionogi Overview
11.13.3 Shionogi Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2016-2021)
11.13.4 Shionogi Product Description
11.13.5 Shionogi Related Developments

12 Value Chain and Sales Channels Analysis
12.1 Opioid-Induced Constipation Value Chain Analysis
12.2 Opioid-Induced Constipation Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Opioid-Induced Constipation Production Mode & Process
12.4 Opioid-Induced Constipation Sales and Marketing
12.4.1 Opioid-Induced Constipation Sales Channels
12.4.2 Opioid-Induced Constipation Distributors
12.5 Opioid-Induced Constipation Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Opioid-Induced Constipation Industry Trends
13.2 Opioid-Induced Constipation Market Drivers
13.3 Opioid-Induced Constipation Market Challenges
13.4 Opioid-Induced Constipation Market Restraints

14 Key Findings in The Global Opioid-Induced Constipation Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Opioid-Induced Constipation Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Methylnaltrexone Bromide
Table 3. Major Manufacturers of Lubiprostone
Table 4. Major Manufacturers of Naloxegol
Table 5. Major Manufacturers of Others
Table 6. Global Opioid-Induced Constipation Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
Table 7. Global Opioid-Induced Constipation Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
Table 8. Global Opioid-Induced Constipation Sales by Region (2016-2021) & (K Units)
Table 9. Global Opioid-Induced Constipation Sales Market Share by Region (2016-2021)
Table 10. Global Opioid-Induced Constipation Sales by Region (2016-2021) & (K Units)
Table 11. Global Opioid-Induced Constipation Sales Market Share by Region (2022-2027)
Table 12. Global Opioid-Induced Constipation Revenue by Region (2016-2021) & (US$ Million)
Table 13. Global Opioid-Induced Constipation Revenue Market Share by Region (2016-2021)
Table 14. Global Opioid-Induced Constipation Revenue by Region (2022-2027) & (US$ Million)
Table 15. Global Opioid-Induced Constipation Revenue Market Share by Region (2022-2027)
Table 16. Global Opioid-Induced Constipation Sales by Manufacturers (2016-2021) & (K Units)
Table 17. Global Opioid-Induced Constipation Sales Share by Manufacturers (2016-2021)
Table 18. Global Opioid-Induced Constipation Revenue by Manufacturers (2016-2021) & (US$ Million)
Table 19. Global Opioid-Induced Constipation Revenue Share by Manufacturers (2016-2021)
Table 20. Opioid-Induced Constipation Price by Manufacturers 2016-2021 (USD/Unit)
Table 21. Global Opioid-Induced Constipation Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Opioid-Induced Constipation by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Opioid-Induced Constipation as of 2020)
Table 23. Opioid-Induced Constipation Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Opioid-Induced Constipation Product Offered
Table 25. Date of Manufacturers Enter into Opioid-Induced Constipation Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 28. Global Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 29. Global Opioid-Induced Constipation Sales Share by Type (2016-2021)
Table 30. Global Opioid-Induced Constipation Sales Share by Type (2022-2027)
Table 31. Global Opioid-Induced Constipation Revenue by Type (2016-2021) & (US$ Million)
Table 32. Global Opioid-Induced Constipation Revenue by Type (2022-2027) & (US$ Million)
Table 33. Global Opioid-Induced Constipation Revenue Share by Type (2016-2021)
Table 34. Global Opioid-Induced Constipation Revenue Share by Type (2022-2027)
Table 35. Opioid-Induced Constipation Price by Type (2016-2021) & (USD/Unit)
Table 36. Global Opioid-Induced Constipation Price Forecast by Type (2022-2027) & (USD/Unit)
Table 37. Global Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 38. Global Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 39. Global Opioid-Induced Constipation Sales Share by Application (2016-2021)
Table 40. Global Opioid-Induced Constipation Sales Share by Application (2022-2027)
Table 41. Global Opioid-Induced Constipation Revenue by Application (2016-2021) & (US$ Million)
Table 42. Global Opioid-Induced Constipation Revenue by Application (2022-2027) & (US$ Million)
Table 43. Global Opioid-Induced Constipation Revenue Share by Application (2016-2021)
Table 44. Global Opioid-Induced Constipation Revenue Share by Application (2022-2027)
Table 45. Opioid-Induced Constipation Price by Application (2016-2021) & (USD/Unit)
Table 46. Global Opioid-Induced Constipation Price Forecast by Application (2022-2027) & (USD/Unit)
Table 47. North America Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 48. North America Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 49. North America Opioid-Induced Constipation Revenue by Type (2016-2021) & (US$ Million)
Table 50. North America Opioid-Induced Constipation Revenue by Type (2022-2027) & (US$ Million)
Table 51. North America Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 52. North America Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 53. North America Opioid-Induced Constipation Revenue by Application (2016-2021) & (US$ Million)
Table 54. North America Opioid-Induced Constipation Revenue by Application (2022-2027) & (US$ Million)
Table 55. North America Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 56. North America Opioid-Induced Constipation Sales by Country (2022-2027) & (K Units)
Table 57. North America Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
Table 58. North America Opioid-Induced Constipation Revenue by Country (2022-2027) & (US$ Million)
Table 59. Europe Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 60. Europe Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 61. Europe Opioid-Induced Constipation Revenue by Type (2016-2021) & (US$ Million)
Table 62. Europe Opioid-Induced Constipation Revenue by Type (2022-2027) & (US$ Million)
Table 63. Europe Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 64. Europe Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 65. Europe Opioid-Induced Constipation Revenue by Application (2016-2021) & (US$ Million)
Table 66. Europe Opioid-Induced Constipation Revenue by Application (2022-2027) & (US$ Million)
Table 67. Europe Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 68. Europe Opioid-Induced Constipation Sales by Country (2022-2027) & (K Units)
Table 69. Europe Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
Table 70. Europe Opioid-Induced Constipation Revenue by Country (2022-2027) & (US$ Million)
Table 71. Asia Pacific Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 72. Asia Pacific Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 73. Asia Pacific Opioid-Induced Constipation Revenue by Type (2016-2021) & (US$ Million)
Table 74. Asia Pacific Opioid-Induced Constipation Revenue by Type (2022-2027) & (US$ Million)
Table 75. Asia Pacific Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 76. Asia Pacific Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 77. Asia Pacific Opioid-Induced Constipation Revenue by Application (2016-2021) & (US$ Million)
Table 78. Asia Pacific Opioid-Induced Constipation Revenue by Application (2022-2027) & (US$ Million)
Table 79. Asia Pacific Opioid-Induced Constipation Sales by Region (2016-2021) & (K Units)
Table 80. Asia Pacific Opioid-Induced Constipation Sales by Region (2022-2027) & (K Units)
Table 81. Asia Pacific Opioid-Induced Constipation Revenue by Region (2016-2021) & (US$ Million)
Table 82. Asia Pacific Opioid-Induced Constipation Revenue by Region (2022-2027) & (US$ Million)
Table 83. Latin America Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 84. Latin America Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 85. Latin America Opioid-Induced Constipation Revenue by Type (2016-2021) & (US$ Million)
Table 86. Latin America Opioid-Induced Constipation Revenue by Type (2022-2027) & (US$ Million)
Table 87. Latin America Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 88. Latin America Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 89. Latin America Opioid-Induced Constipation Revenue by Application (2016-2021) & (US$ Million)
Table 90. Latin America Opioid-Induced Constipation Revenue by Application (2022-2027) & (US$ Million)
Table 91. Latin America Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 92. Latin America Opioid-Induced Constipation Sales by Country (2022-2027) & (K Units)
Table 93. Latin America Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
Table 94. Latin America Opioid-Induced Constipation Revenue by Country (2022-2027) & (US$ Million)
Table 95. Middle East and Africa Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
Table 96. Middle East and Africa Opioid-Induced Constipation Sales by Type (2022-2027) & (K Units)
Table 97. Middle East and Africa Opioid-Induced Constipation Revenue by Type (2016-2021) & (US$ Million)
Table 98. Middle East and Africa Opioid-Induced Constipation Revenue by Type (2022-2027) & (US$ Million)
Table 99. Middle East and Africa Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
Table 100. Middle East and Africa Opioid-Induced Constipation Sales by Application (2022-2027) & (K Units)
Table 101. Middle East and Africa Opioid-Induced Constipation Revenue by Application (2016-2021) & (US$ Million)
Table 102. Middle East and Africa Opioid-Induced Constipation Revenue by Application (2022-2027) & (US$ Million)
Table 103. Middle East and Africa Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 104. Middle East and Africa Opioid-Induced Constipation Sales by Country (2022-2027) & (K Units)
Table 105. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
Table 106. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2022-2027) & (US$ Million)
Table 107. Takeda Pharmaceuticals Corporation Information
Table 108. Takeda Pharmaceuticals Description and Major Businesses
Table 109. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 110. Takeda Pharmaceuticals Opioid-Induced Constipation Product
Table 111. Takeda Pharmaceuticals Recent Developments
Table 112. Bayer Corporation Information
Table 113. Bayer Description and Major Businesses
Table 114. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 115. Bayer Opioid-Induced Constipation Product
Table 116. Bayer Recent Developments
Table 117. Sanofi Corporation Information
Table 118. Sanofi Description and Major Businesses
Table 119. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 120. Sanofi Opioid-Induced Constipation Product
Table 121. Sanofi Recent Developments
Table 122. Mallinckrodt Corporation Information
Table 123. Mallinckrodt Description and Major Businesses
Table 124. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 125. Mallinckrodt Opioid-Induced Constipation Product
Table 126. Mallinckrodt Recent Developments
Table 127. Salix (Bausch Health) Corporation Information
Table 128. Salix (Bausch Health) Description and Major Businesses
Table 129. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 130. Salix (Bausch Health) Opioid-Induced Constipation Product
Table 131. Salix (Bausch Health) Recent Developments
Table 132. AstraZeneca Corporation Information
Table 133. AstraZeneca Description and Major Businesses
Table 134. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 135. AstraZeneca Opioid-Induced Constipation Product
Table 136. AstraZeneca Recent Developments
Table 137. Progenics Pharmaceuticals Corporation Information
Table 138. Progenics Pharmaceuticals Description and Major Businesses
Table 139. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 140. Progenics Pharmaceuticals Opioid-Induced Constipation Product
Table 141. Progenics Pharmaceuticals Recent Developments
Table 142. Purdue Pharm Corporation Information
Table 143. Purdue Pharm Description and Major Businesses
Table 144. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 145. Purdue Pharm Opioid-Induced Constipation Product
Table 146. Purdue Pharm Recent Developments
Table 147. Nektar Therapeutics Corporation Information
Table 148. Nektar Therapeutics Description and Major Businesses
Table 149. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 150. Nektar Therapeutics Opioid-Induced Constipation Product
Table 151. Nektar Therapeutics Recent Developments
Table 152. Daiichi Sankyo Corporation Information
Table 153. Daiichi Sankyo Description and Major Businesses
Table 154. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 155. Daiichi Sankyo Opioid-Induced Constipation Product
Table 156. Daiichi Sankyo Recent Developments
Table 157. Prestige Corporation Information
Table 158. Prestige Description and Major Businesses
Table 159. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 160. Prestige Opioid-Induced Constipation Product
Table 161. Prestige Recent Developments
Table 162. GSK Corporation Information
Table 163. GSK Description and Major Businesses
Table 164. GSK Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 165. GSK Opioid-Induced Constipation Product
Table 166. GSK Recent Developments
Table 167. Shionogi Corporation Information
Table 168. Shionogi Description and Major Businesses
Table 169. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 170. Shionogi Opioid-Induced Constipation Product
Table 171. Shionogi Recent Developments
Table 172. Key Raw Materials Lists
Table 173. Raw Materials Key Suppliers Lists
Table 174. Opioid-Induced Constipation Distributors List
Table 175. Opioid-Induced Constipation Customers List
Table 176. Opioid-Induced Constipation Market Trends
Table 177. Opioid-Induced Constipation Market Drivers
Table 178. Opioid-Induced Constipation Market Challenges
Table 179. Opioid-Induced Constipation Market Restraints
Table 180. Research Programs/Design for This Report
Table 181. Key Data Information from Secondary Sources
Table 182. Key Data Information from Primary Sources
List of Figures
Figure 1. Opioid-Induced Constipation Product Picture
Figure 2. Global Opioid-Induced Constipation Market Share by Type in 2020 & 2027
Figure 3. Methylnaltrexone Bromide Product Picture
Figure 4. Lubiprostone Product Picture
Figure 5. Naloxegol Product Picture
Figure 6. Others Product Picture
Figure 7. Global Opioid-Induced Constipation Sales Market Share by Application in 2020 & 2027
Figure 8. Hospital
Figure 9. Pharmacy
Figure 10. Opioid-Induced Constipation Report Years Considered
Figure 11. Global Opioid-Induced Constipation Sales 2016-2027 (K Units)
Figure 12. Global Opioid-Induced Constipation Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Opioid-Induced Constipation Revenue 2016-2027 (US$ Million)
Figure 14. Global Opioid-Induced Constipation Revenue Market Share by Region in Percentage: 2020 Versus 2027
Figure 15. Global Opioid-Induced Constipation Sales Market Share by Region (2016-2021)
Figure 16. Global Opioid-Induced Constipation Sales Market Share by Region (2022-2027)
Figure 17. North America Opioid-Induced Constipation Sales YoY (2016-2027) & (K Units)
Figure 18. North America Opioid-Induced Constipation Revenue YoY (2016-2027) & (US$ Million)
Figure 19. Europe Opioid-Induced Constipation Sales YoY (2016-2027) & (K Units)
Figure 20. Europe Opioid-Induced Constipation Revenue YoY (2016-2027) & (US$ Million)
Figure 21. Asia-Pacific Opioid-Induced Constipation Sales YoY (2016-2027) & (K Units)
Figure 22. Asia-Pacific Opioid-Induced Constipation Revenue YoY (2016-2027) & (US$ Million)
Figure 23. Latin America Opioid-Induced Constipation Sales YoY (2016-2027) & (K Units)
Figure 24. Latin America Opioid-Induced Constipation Revenue YoY (2016-2027) & (US$ Million)
Figure 25. Middle East & Africa Opioid-Induced Constipation Sales YoY (2016-2027) & (K Units)
Figure 26. Middle East & Africa Opioid-Induced Constipation Revenue YoY (2016-2027) & (US$ Million)
Figure 27. The Top 10 and Top 5 Players Market Share by Opioid-Induced Constipation Sales in 2020
Figure 28. The Top 10 and Top 5 Players Market Share by Opioid-Induced Constipation Revenue in 2020
Figure 29. Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
Figure 30. Global Opioid-Induced Constipation Sales Market Share by Type (2016-2027)
Figure 31. Global Opioid-Induced Constipation Revenue Market Share by Type (2016-2027)
Figure 32. Global Opioid-Induced Constipation Sales Market Share by Application (2016-2027)
Figure 33. Global Opioid-Induced Constipation Revenue Market Share by Application (2016-2027)
Figure 34. North America Opioid-Induced Constipation Sales Market Share by Type (2016-2027)
Figure 35. North America Opioid-Induced Constipation Revenue Market Share by Type (2016-2027)
Figure 36. North America Opioid-Induced Constipation Sales Market Share by Application (2016-2027)
Figure 37. North America Opioid-Induced Constipation Revenue Market Share by Application (2016-2027)
Figure 38. North America Opioid-Induced Constipation Sales Share by Country (2016-2027)
Figure 39. North America Opioid-Induced Constipation Revenue Share by Country (2016-2027)
Figure 40. U.S. Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 41. Canada Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 42. Europe Opioid-Induced Constipation Sales Market Share by Type (2016-2027)
Figure 43. Europe Opioid-Induced Constipation Revenue Market Share by Type (2016-2027)
Figure 44. Europe Opioid-Induced Constipation Sales Market Share by Application (2016-2027)
Figure 45. Europe Opioid-Induced Constipation Revenue Market Share by Application (2016-2027)
Figure 46. Europe Opioid-Induced Constipation Sales Share by Country (2016-2027)
Figure 47. Europe Opioid-Induced Constipation Revenue Share by Country (2016-2027)
Figure 48. Germany Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 49. France Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 50. U.K. Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 51. Italy Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 52. Russia Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 53. Asia Pacific Opioid-Induced Constipation Sales Market Share by Type (2016-2027)
Figure 54. Asia Pacific Opioid-Induced Constipation Revenue Market Share by Type (2016-2027)
Figure 55. Asia Pacific Opioid-Induced Constipation Sales Market Share by Application (2016-2027)
Figure 56. Asia Pacific Opioid-Induced Constipation Revenue Market Share by Application (2016-2027)
Figure 57. Asia Pacific Opioid-Induced Constipation Sales Share by Region (2016-2027)
Figure 58. Asia Pacific Opioid-Induced Constipation Revenue Share by Region (2016-2027)
Figure 59. China Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 60. Japan Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 61. South Korea Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 62. India Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 63. Australia Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 64. Taiwan Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 65. Indonesia Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 66. Thailand Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 67. Malaysia Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 68. Philippines Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 69. Latin America Opioid-Induced Constipation Sales Market Share by Type (2016-2027)
Figure 70. Latin America Opioid-Induced Constipation Revenue Market Share by Type (2016-2027)
Figure 71. Latin America Opioid-Induced Constipation Sales Market Share by Application (2016-2027)
Figure 72. Latin America Opioid-Induced Constipation Revenue Market Share by Application (2016-2027)
Figure 73. Latin America Opioid-Induced Constipation Sales Share by Country (2016-2027)
Figure 74. Latin America Opioid-Induced Constipation Revenue Share by Country (2016-2027)
Figure 75. Mexico Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 76. Brazil Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 77. Argentina Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 78. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Type (2016-2027)
Figure 79. Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Type (2016-2027)
Figure 80. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Application (2016-2027)
Figure 81. Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Application (2016-2027)
Figure 82. Middle East and Africa Opioid-Induced Constipation Sales Share by Country (2016-2027)
Figure 83. Middle East and Africa Opioid-Induced Constipation Revenue Share by Country (2016-2027)
Figure 84. Turkey Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 85. Saudi Arabia Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 86. U.A.E Opioid-Induced Constipation Revenue (2016-2027) & (US$ Million)
Figure 87. Opioid-Induced Constipation Value Chain
Figure 88. Opioid-Induced Constipation Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed